Advertisement.

Hilary Kramer

share

A lot of cannabis investors like to think every state that opens up to recreational sales will dramatically expand the market, as well as turning another spot on the map bright green. I’ve never been a fan of that theory. As far as I’m concerned, people will travel to get the regulatory framework they want, […]

share

The U.S. economy has everything it needs to come back from the pandemic with a boom. Vaccines are coming as the virus recedes. Pent-up demand is building on robust retail sales. And corporate earnings throughout much of the market are on the way back up. We haven’t seen growth forecasts like this since the 2017 […]

share

To hear some investors talk, you’d think Treasury yields above 1.7% were a clear sign of the end of the world approaching. But history proves it takes a lot more than this to shake Wall Street’s confidence. Late in 2019, when volatility was unusually low and there were few clouds on the market horizon, bonds […]

share

This week’s big headline came from a cannabis company Wall Street had written off for dead. It turns out that Hexo Corp. (NASDAQ:HEXO) is now generating positive cash flow. It’s a breakthrough. While the absolute numbers are still on the small side — $202,000 in earnings before interest, taxes, depreciation and amortization (EBITDA) last quarter […]

Beat Earnings
share

Talk on Wall Street lately has turned to whether it’s the end of the world. After all, the Nasdaq is down 7% from its peak and long-term interest rates are inching higher. On the surface, it seems like the wrong season to be talking about stocks handing investors triple-digit-percentage gains, but that is exactly why […]

share

Speaking of triple-digit-percentage trajectories, I see that my proprietary cannabis basket is up 96% so far this year. That performance puts this industry in the top tier of the entire market… and it’s exactly the kind of return I want to capture. This week hasn’t been great, but we still see stocks like OrganiGram Holdings […]